PriceTargets.com logo

Brookline Capital Acquisition Stock Recommendations and Price Targets

Brookline Capital Acquisition logo
Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.
Read More

This is a list of recent ratings by Brookline Capital Acquisition.

DateCompany NameActionCurrent
Price		Price
Target		Rating
3/9/2026
SCYX
SCYNEXIS
 Reiterated Rating$1.00Buy ➝ Buy
3/3/2026
NTLA
Intellia Therapeutics
 Reiterated Rating$13.00Buy ➝ Buy
2/23/2026
CCCC
C4 Therapeutics
 Boost Price Target$3.00$20.00 ➝ $30.00Buy ➝ Buy
2/3/2026
IMUX
Immunic
 Upgrade$1.00Strong-Buy
2/3/2026
CRDL
Cardiol Therapeutics
 Upgrade$1.00Strong-Buy
2/3/2026
CGTX
Cognition Therapeutics
 Upgrade$1.00Strong-Buy
2/3/2026
CRVO
CervoMed
 Upgrade$4.00Strong-Buy
2/3/2026
ECOR
electroCore
 Upgrade$6.00Strong-Buy
1/29/2026
QNCX
Quince Therapeutics
 Downgrade$0.00Strong-Buy ➝ Hold
1/21/2026
RNTX
Rein Therapeutics
 Downgrade$1.00Buy ➝ Hold
1/21/2026
LSTA
Lisata Therapeutics
 Downgrade$5.00Buy ➝ Hold
1/7/2026
IMNN
Imunon
 Reiterated Rating$3.00Buy ➝ Buy
12/18/2025
VRCA
Verrica Pharmaceuticals
 Upgrade$6.00 $17.00Hold ➝ Buy
12/1/2025
IRD
Opus Genetics
 Upgrade$5.00Strong-Buy
11/3/2025
RNTX
Rein Therapeutics
 Upgrade$1.00Hold ➝ Buy
9/17/2025
CRDL
Cardiol Therapeutics
 Upgrade$1.00Strong-Buy
8/21/2025
BIOX
Bioceres Crop Solutions
 Downgrade$1.00Strong-Buy ➝ Hold
8/19/2025
RNTX
Rein Therapeutics
 Downgrade$1.00Buy ➝ Hold
8/13/2025
ICCM
IceCure Medical
 Reiterated Rating$1.00Buy ➝ Buy
7/21/2025
RADX
Radiopharm Theranostics
 Initiated Coverage$5.00 $18.00Buy
7/15/2025
LSTA
Lisata Therapeutics
 Boost Price Target$5.00$20.00 ➝ $32.00Buy ➝ Buy
7/9/2025
CADL
Candel Therapeutics
 Upgrade$5.00Strong-Buy
6/23/2025
HURA
TuHURA Biosciences
 Upgrade$2.00Strong-Buy
5/13/2025
PALI
Palisade Bio
 Reiterated Rating$2.00$16.00 ➝ $16.00Buy ➝ Buy
3/18/2025
BIVI
BioVie
 Upgrade$1.00Strong-Buy
3/11/2025
CRVO
CervoMed
 Upgrade$4.00Hold ➝ Strong-Buy
3/10/2025
CATX
Perspective Therapeutics
 Upgrade$5.00Strong-Buy
2/10/2025
MRKR
Marker Therapeutics
 Upgrade$1.00Strong-Buy
1/27/2025
CGTX
Cognition Therapeutics
 Upgrade$1.00Strong-Buy
12/23/2024
MDCX
Medicus Pharma
 Upgrade$0.00Strong-Buy
12/23/2024
EXEL
Exelixis
 Initiated Coverage$42.00Buy
12/18/2024
QNCX
Quince Therapeutics
 Initiated Coverage$0.00 $9.00Buy
12/10/2024
CRVO
CervoMed
 Downgrade$4.00Strong-Buy ➝ Hold
11/20/2024
PALI
Palisade Bio
 Initiated Coverage$2.00 $38.00Buy
11/15/2024
HYPD
Hyperion DeFi
 Reiterated Rating$3.00Buy ➝ Hold
11/13/2024
SYRS
Syros Pharmaceuticals
 Reiterated Rating$0.00Buy ➝ Hold
10/14/2024
COCH
Envoy Medical
 Initiated Coverage$1.00 $9.00Buy
10/2/2024
VRCA
Verrica Pharmaceuticals
 Reiterated Rating$6.00Buy ➝ Hold
8/22/2024
OSTX
OS Therapies
 Upgrade$2.00Strong-Buy
7/22/2024
IBIO
iBio
 Initiated Coverage$2.00 $3.60Buy
7/9/2024
UNCY
Unicycive Therapeutics
 Upgrade$7.00Strong-Buy
7/8/2024
CRVO
CervoMed
 Initiated Coverage$4.00 $63.00Buy
6/7/2024
SABS
SAB Biotherapeutics
 Initiated Coverage$5.00 $8.00Buy
5/30/2024
FBRX
Forte Biosciences
 Initiated Coverage$27.00 $4.00Buy
5/15/2024
DARE
Dare Bioscience
 Upgrade$2.00 $36.00Hold ➝ Buy
4/17/2024
DARE
Dare Bioscience
 Downgrade$2.00Buy ➝ Hold
4/5/2024
IMUX
Immunic
 Reiterated Rating$1.00 $10.00Buy
3/4/2024
ATBPF
Antibe Therapeutics
 Downgrade$0.00Buy ➝ Hold
2/28/2024
ANVS
Annovis Bio
 Downgrade$2.00 $9.00Buy ➝ Hold
1/25/2024
OTLK
Oncobiologics
 Upgrade$0.00 $31.40Hold ➝ Buy
12/7/2023
HEPA
Hepion Pharmaceuticals
 Downgrade$0.00Buy ➝ Hold
11/30/2023
LNTH
Lantheus
 Initiated Coverage$83.00 $100.00Buy
11/15/2023
SQZB
SQZ Biotechnologies
 Downgrade$0.00Buy ➝ Hold
11/10/2023
ANVS
Annovis Bio
 Reiterated Rating$2.00 $35.00Buy
10/30/2023
GNLX
Genelux
 Upgrade$3.00Hold ➝ Buy
10/17/2023
HYPD
Hyperion DeFi
 Initiated Coverage$3.00 $640.00Buy
10/12/2023
EDSA
Edesa Biotech
 Reiterated Rating$7.00 $57.00Buy ➝ Buy
8/30/2023
OTLK
Oncobiologics
 Downgrade$0.00Buy ➝ Hold
8/14/2023
ATBPF
Antibe Therapeutics
 Reiterated Rating$0.00Buy